Cue Biopharma (NASDAQ:CUE) VP Michael Vincent Meluzio Sells 5,628 Shares of Stock

Cue Biopharma, Inc. (NASDAQ:CUE) VP Michael Vincent Meluzio sold 5,628 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $30.09, for a total value of $169,346.52. Following the completion of the transaction, the vice president owned 48,961 shares of the company’s stock, valued at $1,473,236.49. This represents a 10.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Cue Biopharma Price Performance

Shares of Cue Biopharma stock traded down $6.56 during trading on Monday, hitting $27.64. 305,202 shares of the company’s stock traded hands, compared to its average volume of 363,425. Cue Biopharma, Inc. has a 1 year low of $4.97 and a 1 year high of $45.50. The stock has a market capitalization of $116.09 million, a P/E ratio of -1.02 and a beta of 2.47. The business has a 50-day simple moving average of $29.50 and a 200-day simple moving average of $146.00.

Cue Biopharma (NASDAQ:CUE) last released its quarterly earnings data on Friday, August 14th. The company reported ($24.14) EPS for the quarter, missing the consensus estimate of ($1.69) by ($22.45). Cue Biopharma had a negative return on equity of 482.58% and a negative net margin of 435.83%.The business had revenue of $7.88 million during the quarter, compared to the consensus estimate of $3.00 million.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on CUE. Wall Street Zen cut shares of Cue Biopharma from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cue Biopharma in a research report on Thursday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CUE. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Cue Biopharma by 730.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after acquiring an additional 73,000 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Cue Biopharma in the 3rd quarter worth $62,000. Stifel Financial Corp increased its stake in shares of Cue Biopharma by 25.4% in the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after purchasing an additional 50,000 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc raised its holdings in Cue Biopharma by 1,231.2% in the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after purchasing an additional 407,568 shares during the period. Finally, Boothbay Fund Management LLC raised its holdings in Cue Biopharma by 15.3% in the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after purchasing an additional 93,333 shares during the period. 35.04% of the stock is currently owned by institutional investors.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.